Literature DB >> 9360560

Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation.

O Gimm1, D J Marsh, S D Andrew, A Frilling, P L Dahia, L M Mulligan, J D Zajac, B G Robinson, C Eng.   

Abstract

The autosomal dominant multiple endocrine neoplasia type 2 syndromes (MEN 2) comprise three clinically distinct entities, MEN 2A, familial medullary thyroid carcinoma and MEN 2B, which share a common clinical feature: medullary thyroid carcinoma (MTC). MEN 2B is considered to have the most aggressive form of MTC. Therefore, early detection of MEN 2B in order to prevent potentially lethal MTC is important. More than 95% of all MEN 2B cases are caused by germline mutation at codon 918 (M918T) in exon 16 of the RET proto-oncogene. In this study, we demonstrate the presence of germline codon 883 mutation (A883F) in 2 of 3 unrelated MEN 2B cases without codon 918 mutation. Our data demonstrate a novel etiologic event which may have roles in predisposition to MEN 2B when present in the germline and in the pathogenesis of sporadic MTC when somatic.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360560     DOI: 10.1210/jcem.82.11.4508

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  47 in total

Review 1.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Oral Mucosal Neuromas Leading to the Diagnosis of Multiple Endocrine Neoplasia Type 2B in a Child With Intestinal Pseudo-obstruction.

Authors:  Cary M Qualia; Marilyn R Brown; Charlotte K Ryan; Thomas M Rossi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 3.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

4.  Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.

Authors:  Sina Jasim; Anita K Ying; Steven G Waguespack; Thereasa A Rich; Elizabeth G Grubbs; Camilo Jimenez; Mimi I Hu; Gilbert Cote; Mouhammed Amir Habra
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

5.  [Prophylactic thyroid surgery].

Authors:  A Frilling; F Weber
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

Review 6.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

7.  Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B.

Authors:  Angeliki Makri; Srivandana Akshintala; Claudia Derse-Anthony; Jaydira Del Rivero; Brigitte Widemann; Constantine A Stratakis; John Glod; Maya Lodish
Journal:  J Clin Endocrinol Metab       Date:  2019-01-01       Impact factor: 5.958

8.  Hirschsprung disease of the colon, a vaginal mass and medullary thyroid cancer - a RET oncogene driven problem.

Authors:  Romy Pandey; Tiffany Thurow; Robert de W Marsh
Journal:  J Gastrointest Oncol       Date:  2011-12

Review 9.  Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.

Authors:  Samuel A Wells
Journal:  Endocr Relat Cancer       Date:  2017-11-15       Impact factor: 5.678

10.  Multiple Endocrine Neoplasia Type 2B Presents Early in Childhood but Often Is Undiagnosed for Years.

Authors:  Angeliki Makri; Srivandana Akshintala; Claudia Derse-Anthony; Brigitte Widemann; Constantine A Stratakis; John Glod; Maya Lodish
Journal:  J Pediatr       Date:  2018-10-09       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.